Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Bullish +75

EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

🏛️ The European Commission has granted marketing authorization for Amgen's IMDYLLTRA® (tarlatamab) as a monotherapy for extensive-stage small cell lung cancer (ES-SCLC).

💊 This approval is specifically for adult patients requiring systemic therapy after disease progression on or after first-line platinum-based chemotherapy.

📉 The decision was based on the DeLLphi-304 Phase 3 trial, which showed a 40% reduction in the risk of death compared to standard-of-care chemotherapy.

⏳ Patients treated with IMDYLLTRA experienced a median overall survival of 13.6 months versus 8.3 months for those receiving chemotherapy alone.

🎯 IMDYLLTRA is the first and only T-cell engager therapy approved by the European Commission for the treatment of small cell lung cancer.

🔬 The drug works by binding to DLL3 on tumor cells and CD3 on T cells, activating T cells to kill cancer cells expressing the DLL3 protein.

⚠️ Cytokine release syndrome (CRS) was the most common adverse reaction, occurring in 56.7% of patients, primarily after the first two doses.

🧠 Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 4.7% of patients and can occur up to several weeks after administration.

🩸 Neutropenia was reported in 16.9% of patients, with grade 3 or 4 events occurring in 8.2% of the study population.

⚖️ The safety profile was consistent with known risks for this class of therapy, including serious infections and elevated liver enzymes.

🏥 Patients must be monitored from the start of infusion for 6 to 8 hours on Cycle 1 Day 1 and Day 8 in an appropriate healthcare setting.

💉 The recommended dosing schedule involves an initial dose of 1 mg on day 1 followed by 10 mg on days 8, 15, and every 2 weeks thereafter.

👩‍⚕️ Physicians experienced in cancer therapy must supervise the administration of IMDYLLTRA to manage severe reactions like CRS and neurologic toxicity.

🤝 Amgen's broader DeLLphi clinical program continues to evaluate tarlatamab in combination regimens and earlier stages of SCLC.

📰 Results from the pivotal DeLLphi-304 trial were previously presented at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine.

Bullish Signals
  • The European Commission has granted marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy to treat adults with extensive-stage small cell lung cancer (ES-SCLC) who have progressed after first-line platinum-based chemotherapy.
  • The approval is based on the DeLLphi-304 Phase 3 trial, which demonstrated a significant survival benefit over standard of care chemotherapy, reducing the risk of death by 40% and extending median overall survival by more than five months (13.6 vs. 8.3 months).
  • IMDYLLTRA® is the first and only T-cell engager therapy approved to treat small cell lung cancer in Europe, marking a major milestone for patients with this aggressive disease.
  • The drug targets DLL3, a protein expressed on the surface of SCLC cells in up to 96% of patients, while being minimally expressed on healthy cells, offering a highly specific mechanism of action.
  • Amgen's robust clinical development program includes multiple ongoing Phase 3 studies (DeLLphi-303 through DeLLphi-313) evaluating IMDYLLTRA in earlier stages of SCLC and as part of combination regimens.
  • Results from the pivotal DeLLphi-304 study were reviewed at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine, validating the drug's efficacy in a global setting.
  • The safety profile was consistent with known characteristics, with manageable adverse reactions such as cytokine release syndrome (CRS) occurring primarily after the first two doses and resolving with appropriate monitoring and supportive care.
Risk Factors
  • Cytokine release syndrome (CRS) occurred in 56.7% of patients, with serious CRS events reported in 19.7%, and fatal CRS cases have been reported in the post-marketing setting.
  • Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), occurred in 65% of patients, with life-threatening or fatal reactions reported, including one fatal ICANS case.
  • Treatment discontinuation due to CRS was required for 0.6% of patients, and treatment interruption or dose modification occurred in 2.1% of patients.
  • Serious infections, including life-threatening and fatal infections, have been reported in patients treated with IMDYLLTRA, with opportunistic infections occurring in 43% of the pooled safety population.
  • Hepatotoxicity was observed in the pooled safety population, with elevated ALT in 39% of patients and elevated AST in 43%, including Grade 3 or 4 events in 2.5% and 3.2% respectively.
  • Cytopenias are a significant risk, with decreased neutrophils occurring in 16% of patients (including 8.2% Grade 3 or 4) and decreased platelets in 30% (including 2.2% Grade 3 or 4).
  • The drug requires administration in an appropriate healthcare facility equipped to monitor and manage severe reactions like CRS and ICANS, limiting accessibility for patients.
  • Patients must remain within proximity of a healthcare facility for up to 48 hours following initial infusions, imposing logistical burdens on caregivers and patients.
  • Hypersensitivity reactions, including rare severe events such as bronchospasm, have been reported in patients treated with IMDYLLTRA.
Full Analysis
Amgen announced that the European Commission has granted marketing authorization for IMDYLLTRA (tarlatamab) as a monotherapy to treat adults with extensive-stage small cell lung cancer (ES-SCLC) who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy. This approval is based on results from the Phase 3 DeLLphi-304 trial, which demonstrated a significant survival benefit over standard of care chemotherapy in this setting. The trial showed that IMDYLLTRA reduced the risk of death by 40% and extended median overall survival by more than five months compared to chemotherapy (median OS: 13.6 vs. 8.3 months; hazard ratio, 0.60). IMDYLLTRA is a first-in-class targeted immunotherapy engineered to bind to DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing SCLC cells. The drug was evaluated in the DeLLphi-304 study involving 509 patients randomized to receive either IMDYLLTRA or local standard of care chemotherapy (topotecan in most countries, with variations in the U.S., Canada, Australia, Singapore, South Korea, and Japan). Results were reviewed at the 2025 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine. The safety profile for IMDYLLTRA was consistent with its known profile, with cytokine release syndrome (CRS) being the most common adverse reaction (56.7%), followed by decreased appetite (36.4%) and pyrexia (31.9%). CRS primarily occurred after the first two doses, prompting recommendations for monitoring from the start of infusion for 6 to 8 hours on Cycle 1 Day 1 and Cycle 1 Day 8 in an appropriate healthcare setting. Other common adverse reactions included dysgeusia, constipation, anaemia, fatigue, nausea, asthenia, neutropenia, hyponatraemia, headache, and lymphopenia. Serious adverse reactions included CRS (19.7%) and pyrexia (4.7%). Amgen's robust clinical development program includes the DeLLphi clinical trials, which evaluate IMDYLLTRA as a monotherapy and as part of combination regimens in both earlier stages of SCLC and earlier lines of treatment. The drug is indicated for the treatment of adult patients with ES-SCLC who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy. Patients should be monitored closely for signs and symptoms of CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) during treatment, with specific dosing schedules and monitoring protocols outlined in the Summary of Product Characteristics.